Business
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and
About this update from Red Light Holland Corp
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. Red Light is pleased to confirm additional shipments of Filament Health's PEX010 supporting:","length":685,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"University of Calgary ("UCalgary") - Second shipments in support of ongoing clinical studies in Alcohol Use Disorder and Persistent Post-Concussion Symptoms.","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"University of California, San Francisco ("UCSF") - A second shipment delivered for the UCSF study entitled "A Double-blinded, Active Placebo-Controlled, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People with Chronic Low Back Pain", to enable continued research collaborations in the United States.","length":352,"tagName":"p"}]},{"val":[{"type":"text","content":"A first-time shipment supporting a clinical study at a Canadian academic institution, further expanding PEX010's footprint within Canada's psychedelic research program.","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Compassionate Use Program - Multiple shipments of PEX010 to support patients approved through the compassionate use program, reflecting growing physician and patient demand for pharmaceutical-grade, naturally-derived psilocybin in real-world therapeutic settings.","length":263,"tagName":"p"}]},{"val":[{"type":"text","content":"3rd party lab - A shipment of PEX010 to Filament's contracted third-party analytical laboratory, supporting ongoing quality control, analytical testing, and GMP compliance activities that underpin Filament's manufacturing and supply chain infrastructure.","length":262,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1220,"olType":false},{"type":"text",...